ADC Therapeutics SA

Overview

ADC Therapeutics SA is a clinical-stage biotechnology company focused on the development of antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. The company leverages its proprietary pyrrolobenzodiazepine (PBD) technology to design and develop novel targeted therapies.

Therapeutic areas

API / Drug Master Files

ADC Therapeutics SA holds 4 active (8 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• ADCT-701 DRUG PRODUCTActive2022-08-31
• ADCT-701 DRUG SUBSTANCEActive2022-08-26
• HUBA-1-3D-GAINACN3 MABActive2022-08-22
• PL1601 DRUG LINKERActive2022-08-01
• ADCT-602 DRUG PRODUCTInactive2018-03-02
• ADCT-602 DRUG SUBSTANCEInactive2018-03-01
• HLL2-C220 MONOCLONAL ANTIBODYInactive2018-03-01
• SG-3249 DRUG LINKERInactive2018-01-25

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to ADC Therapeutics SA in our records. PharmaTek screens the full directory against live FDA enforcement data.